-
公开(公告)号:US20110230457A1
公开(公告)日:2011-09-22
申请号:US12973474
申请日:2010-12-20
申请人: Joerg BERGHAUSEN , Nicole BUSCHMANN , Pascal FURET , François GESSIER , Joanna HERGOVICH LISZTWAN , Philipp HOLTZER , Edgar JACOBY , Joerg KALLEN , Keiichi MASUYA , Carole PISSOT SOLDERMANN , Haixia REN , Stefan STUTZ
发明人: Joerg BERGHAUSEN , Nicole BUSCHMANN , Pascal FURET , François GESSIER , Joanna HERGOVICH LISZTWAN , Philipp HOLTZER , Edgar JACOBY , Joerg KALLEN , Keiichi MASUYA , Carole PISSOT SOLDERMANN , Haixia REN , Stefan STUTZ
IPC分类号: A61K31/397 , C07D401/14 , A61K31/497 , A61K31/4725 , C07D401/10 , A61K31/513 , C07D413/14 , A61K31/5377 , A61K31/501 , C07D417/12 , A61K31/541 , A61P35/00
CPC分类号: C07D239/82 , C07D217/24 , C07D401/04 , C07D401/10 , C07D401/12 , C07D401/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/12 , C07D413/10 , C07D413/12 , C07D413/14 , C07D417/12
摘要: The invention relates to substituted nitrogen containing bicyclic heterocycles of the formula (I) wherein Z is CH2 or N—R4 and X, R1, R2, R4, R6, R7 and n are as defined in the description. Such compounds are suitable for the treatment of a disorder or disease which is mediated by the activity of MDM2 and/or MDM4, or variants thereof.
摘要翻译: 本发明涉及式(I)的取代的含氮双环杂环,其中Z是CH 2或N-R 4,X,R 1,R 2,R 4,R 6,R 7和n如说明书中所定义。 这些化合物适用于治疗由MDM2和/或MDM4或其变体的活性介导的病症或疾病。
-
2.
公开(公告)号:US20120129871A1
公开(公告)日:2012-05-24
申请号:US13298351
申请日:2011-11-17
申请人: Joerg BERGHAUSEN , Haixia REN
发明人: Joerg BERGHAUSEN , Haixia REN
IPC分类号: A61K31/496 , A61P35/00 , C07D401/12
CPC分类号: C07D401/12
摘要: A crystalline form of (S)-1-(4-Chloro-phenyl)-7-isopropoxy-6-methoxy-2-(4-{methyl-[4-(4-methyl-3-oxo-piperazin-1-yl)-trans-cyclohexylmethyl]-amino}-phenyl)-1,4-dihydro-2H-isoquinolin-3-one, which is useful in the treatment of a disease or disorder associated with the interaction between p53, or variants thereof, and MDM2 and/or MDM4, or variants thereof, respectively,
摘要翻译: (S)-1-(4-氯 - 苯基)-7-异丙氧基-6-甲氧基-2-(4- {甲基 - [4-(4-甲基-3-氧代 - 哌嗪-1-基) 环己基甲基] - 氨基} - 苯基)-1,4-二氢-2H-异喹啉-3-酮,其可用于治疗与p53或其变体之间的相互作用相关的疾病或病症, 和MDM2和/或MDM4或其变体,
-
公开(公告)号:US20110112121A1
公开(公告)日:2011-05-12
申请号:US12827218
申请日:2010-06-30
申请人: Joerg BERGHAUSEN , Claire HAUG , Michael HERBIG , Bin HU , Stéphane JONAT , Rajender LELETI , Josef Gottfried MEINGASSNER , Stéphanie MONNIER , Matthias NAPP , Mahavir PRASHAD , Anton STÜTZ , Ranjit THAKUR
发明人: Joerg BERGHAUSEN , Claire HAUG , Michael HERBIG , Bin HU , Stéphane JONAT , Rajender LELETI , Josef Gottfried MEINGASSNER , Stéphanie MONNIER , Matthias NAPP , Mahavir PRASHAD , Anton STÜTZ , Ranjit THAKUR
IPC分类号: A61K31/505 , A61P17/00 , A61P17/06 , C07D239/02
CPC分类号: A61K31/505 , A61K9/0014 , A61K47/06 , A61K47/10 , A61K47/14 , C07D239/34
摘要: The present invention relates to pharmaceutical compositions of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide, to the use of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide and compositions of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide in therapeutic applications, especially indications with a dysregulation/overexpression of VEFG, (neo)-vascularisation and VEGF driven angiogenesis and to methods for manufacturing such compositions, the invention further relates to specific forms of 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide and to the manufacturing and use of such forms. The present invention also relates to a new process to produce 6-(6-hydroxymethyl-pyrimidin-4-yloxy)-naphthalene-1-carboxylic acid (3-trifluoromethyl-phenyl)-amide.
摘要翻译: 本发明涉及6-(6-羟基甲基 - 嘧啶-4-基氧基) - 萘-1-羧酸(3-三氟甲基 - 苯基) - 酰胺的药物组合物,其用于6-(6-羟甲基 - 嘧啶 -4-基氧基) - 萘-1-羧酸(3-三氟甲基 - 苯基) - 酰胺和6-(6-羟基甲基 - 嘧啶-4-基氧基) - 萘-1-甲酸(3-三氟甲基 - 苯基) ) - 酰胺在治疗应用中,特别是VEFG(neo)血管形成和VEGF驱动的血管发生的失调/过度表达的适应症以及制备这种组合物的方法,本发明还涉及6-(6-羟甲基嘧啶 -4-基氧基) - 萘-1-羧酸(3-三氟甲基 - 苯基) - 酰胺,并且制备和使用这种形式。 本发明还涉及产生6-(6-羟甲基 - 嘧啶-4-基氧基) - 萘-1-羧酸(3-三氟甲基 - 苯基) - 酰胺的新方法。
-
-